Archive for the ‘COVID-19 Pandemic’ Category

US Army Micro-Atomizer Contributes to COVID-19 Research

Monday, January 18th, 2021

Aberdeen Proving Ground, MD – A device patented by researchers at the U.S. Army Combat Capabilities Development Command Chemical Biological Center (DEVCOM CBC) is being commercialized as a tool in the study of COVID-19.

The micro-atomizer, U.S. Patent 8,882,085, is a device that produces an aerosol spray on a very small scale for studying aerosolized particles inhaled by humans. The micro-atomizer has a .005 in diameter sample pass through — slightly larger than a human hair. This invention allows scientists to scale things down into a much smaller space to model what would happen on a larger scale.

DEVCOM CBC biologist Michael Horsmon, senior engineering technician Richard Kreis, and retired Army scientist Charles Crouse are the inventors behind the micro-atomizer. This product was developed to enable detection, protection and decontamination technology development geared toward protecting the warfighter from toxic chemical agents by simulating those agents on a micro level using aerosol spray.

While the micro-atomizer was developed as a research tool in chemical agent protection, it can also be used to simulate human sneezing, hacking or coughing. This will enable researchers to model the COVID-19 flow that would be expelled by someone who already has it. According to Kreis, “by allowing the molecules to get down to the same size as you would with COVID-19, it is easy to replicate continuously, repeatedly and accurately.”

Techlink, the DoD’s national partnership intermediary for technology transfer typically reviews all government patents and publicizes technologies that are ripe for commercialization. “We were notified by our partner, Techlink who’s in Montana, that there was interest in this patent. Our office investigates the status of patents and if there are existing prototypes. When we investigated, we learned that there were no more prototypes, so we went to the Research and Technology Directorate and asked them if they were willing to fund a few more prototypes because of the commercial interest and they agreed,” said Matt Jones of the Center’s Technology Transfer Office.

The test was a success and the company signed a patent license agreement this year. The inventors are currently focusing on reproducing the micro-atomizer and building the product consistently. The goal is to commercialize it so that it is available worldwide. “Universities, industry and other government agencies can use the micro-atomizer and it can be used in fields ranging from aerobiology, toxicology, and maybe even generating aerosols of coding materials for protection of surfaces. It has a wide range of uses,” Horsmon said.

By Richard M Arndt

DOD utilizes 3D-printing to Create N95 Respirators in the Battle Against COVID-19

Thursday, January 14th, 2021

In response to the COVID-19 global pandemic, the U.S. Army Medical Materiel Development Activity’s Warfighter Expeditionary Medicine and Treatment Project Management Office, as part of the U.S. Army Medical Research and Development Command’s Additive Manufacturing Working Group, has played an integral role in the ramped-up effort to produce N95 respirators for healthcare and frontline workers across the nation. As stated on the U.S. Food and Drug Administration’s website, an N95 respirator is “a respiratory protective device designed to achieve a very close facial fit and very efficient filtration of airborne particles.” Compared to a surgical mask, which is loose-fitting, the edges of the N95 mask are designed to form a very tight seal around the individual’s nose and mouth, providing the highest levels of protection against infection from COVID-19.

U.S. Air Force Maj. Daniel Williams serves as product manager of the WEMT PMO’s N95 respirator efforts at USAMMDA. These include coordinating programmatic and regulatory support, leveraging existing government resources, and developing synergies within the Department of Defense’s organic industrial base to successfully generate N95 respirator products. He explained that his primary task is to ensure the medical device meets military needs and regulatory requirements, and that development of the product remains on schedule and within budget.

In a recent interview, Williams offered a great deal of insight with regard to USAMMDA’s N95 respirator efforts, and the work to produce and distribute these products as quickly as possible in the battle against the spread of COVID-19 throughout our nation and the world.

JS: As product manager within the WEMT PMO, please describe your responsibilities in regard to the N95 respirator effort.

DW: The N95 effort is a slightly atypical experience, in that we are primarily working with DOD partners who have never manufactured medical devices. However, they have extensive experience in various methods of manufacturing, including additive manufacturing, also known as three-dimensional, or 3D, printing. So, our primary responsibility is assisting these DOD manufacturers in navigating the medical device world, including compliance with U.S. Food and Drug Administration and National Institute for Occupational Safety and Health regulations. Further, we facilitate test and evaluation of their products, by leveraging DOD laboratories and government partners to obtain performance feedback on respirator prototypes.

JS: Please describe the features of the N95 respirator, and why this device is superior to others currently on the market. What is its significance, especially with regard to COVID?

DW: It’s not so much superiority, as it is availability. One of the highest levels of respiratory protection for medical purposes, to include viral infection, is a NIOSH-certified N95 respirator. These come in multiple forms, but all are held to the same standard of filtering at least 95 percent of relevant particles, such as the Sudden Acute Respiratory Syndrome Coronavirus-2 virus. Most people are familiar with what is called an FFR, or a Filtering Facepiece Respirator. These are the standard disposable, one-time-use products typically worn by our healthcare workers. However, at this time, these types of masks are nearly impossible to 3D-print. Our group has been working on what is called an elastomeric half-mask respirator, which is a reusable frame produced by a 3D printer, with a disposable media or cartridge that filters at the 95-percent level.

When the pandemic hit, the on-hand supply of N95 respirators, specifically FFRs, was quickly exhausted and traditional N95 manufacturers were not prepared to meet this new demand. Therefore, the primary purpose of the N95 working group is to develop N95 respirators to supplement existing supplies of respirators, as well as to develop new manufacturing capabilities within the DOD’s organic industrial base, which consists of military arsenals, maintenance depots and ammunition factories. Ensuring the DOD has the capability to independently manufacture protective respiratory devices will help to protect frontline workers during the COVID-19 pandemic, and it will also help to maintain our military readiness in the face of future pandemics or biothreats.

JS: Please detail the current status of the N95 program, and explain what lies ahead.

DW: Currently, we’ve partnered with multiple organizations across the DOD including the Army, Navy, Coast Guard, and the Defense Logistics Agency to support N95 respirator design, manufacturing and distribution through existing logistics. To date, we’ve facilitated testing of 18 iterations of respirator design, and two have successfully passed preliminary evaluation at the Army’s Combat Capabilities Development Command’s Chemical Biological Center. Our next steps will be to assist these manufacturers with the NIOSH application and process, to obtain an N95 certification for these respirators. Further, we are continuously seeking new partners within the DOD who have N95-related efforts, so that we may be able to assist.

The COVID-19 pandemic has clearly illustrated that civilian medical supply chains were unprepared to rapidly scale-up production of critical medical supplies such as medical personal protective equipment, including N95 respirators. Although this crisis will end, the next one could come along at any time. Additionally, the impact of critical medical supply shortages on military readiness could occur again in future battlefields from natural pandemics or biothreat agents. By continuing to focus on producing medical devices within the DOD organic industrial base, we can translate the lessons we’ve learned with medical PPE shortages into better preparedness for the next medical crisis, as well as for future conflicts in a Multi-Domain Operational environment.

JS: Why was the WEMT PMO tasked with the N95 respirator effort?

DW: The WEMT PMO’s everyday mission is to develop and deliver medical devices to our Service partners in the Army, Navy, Air Force and Marines. In response to the COVID-19 pandemic, our program office was able to naturally pivot and leverage our staff’s medical product development expertise and apply it to the crisis at hand. This is truly what project managers do – we find creative ways to deliver effective, suitable and timely medical solutions when and where they are needed most.

JS: Please list the other members of the N95 respirator program team, and detail their responsibilities in the overall effort.

DW: The team has been phenomenal and is comprised of many professionals. However, the N95 program is actually a subgroup of the USAMRDC’s Additive Manufacturing Working Group, and nothing could have been accomplished without its assistance and guidance. The AMWG oversees three specific product lines: diagnostic swabs, ventilator parts and accessories, and the N95 respirator. As the lead for the N95 line of effort, I was tasked with outlining FDA and NIOSH requirements, initiating agreements between organizations, and leading an N95 working group to facilitate collaboration amongst all of our partners.

The N95 team specifically, can really be split into three different components, and we’d be nowhere without the ongoing collaborative effort from each component. First are our manufacturing partners, the U.S. Navy Underwater Warfare Center-Keyport, U.S. Forces Korea, Defense Logistics Agency, and the U.S. Coast Guard Academy. These organizations have the technical and subject matter expertise to not only design an N95 respirator, but actually to produce it through additive manufacturing methods.

Second is our AMWG team members at USAMRDC, comprised of the Office of Regulated Activities, Office of the Principal Assistant for Acquisition, Legal office, and USAMMDA’s Office of Research and Technology Applications and the WEMT PMO. The USAMRDC ensures all regulatory requirements for the respirator have been met, appropriate agreements are in place between organizations, and that any concerns with patents or intellectual property on the respirator designs have been addressed. It also provides clinical expertise on potential products, and facilitates test and evaluation of N95 respirator prototypes.

Last, but certainly not least, is the Army’s Combat Capabilities Development Command Chemical Biological Center. The CCDC CBC has been evaluating all forms of respirators for decades, and has an unparalleled knowledge of respirator design and evaluation. Once our manufacturing partners have produced a prototype, it is sent to CCDC CBC for evaluation, to determine whether it will meet the NIOSH standards for an N95 respirator. The CCDC CBC has been critical in providing performance feedback and offering design suggestions for our manufacturers, allowing iterative prototyping to expedite development of respirators.

JS: Other than for the current pandemic, what are some other (future) uses of the N95 mask?

DW: The N95 was thrust into the spotlight as COVID-19 is an airborne respiratory illness. However, the N95 respirator has long been used as medical PPE to prevent against other airborne illnesses, as well as in industrial settings to protect workers against airborne environmental toxins. Therefore, even when the COVID-19 pandemic ends, the N95 respirator will still be a much-needed product in these types of situations.

JS: Is there anything else you would like to say regarding the N95 working group?

DW: Tireless effort is put in on a daily basis, from N95 working group members internal and external to USAMMDA and USAMRDC, USAMMDA’s higher headquarters. It has been such an honor to work with such an amazing group of professionals, spanning the medical and non-medical communities, and a truly unique experience to see so many different specialties come together for a common goal. I am extremely grateful to have been a part of it, and I would like to say a sincere “Thank you” to everyone involved!

USAMMDA is a subordinate command of the U.S. Army Medical Research and Development Command, under the Army Futures Command. As the premier developer of world-class military medical capabilities, USAMMDA is responsible for developing and delivering critical products designed to protect and preserve the lives of Warfighters across the globe. These products include drugs, vaccines, biologics, devices and medical support equipment intended to maximize survival of casualties on the battlefield.

Always Ready: 86th Aeromedical Evacuation Squadron Executes Negatively Pressurized Conex-Lite Training Mission

Tuesday, January 5th, 2021


The 86th Aeromedical Evacuation Squadron held a COVID-19 patient movement training using the Negatively Pressurized Conex-Lite at Ramstein Air Base, Dec. 14-18.

The week-long training ended with a proof-of-concept flight on a C-130J Super Hercules, solidifying the entire process of U.S. Air Forces in Europe and Air Forces Africa COVID-19 patient transfer capabilities for the 86th Airlift Wing.

“It was the first time an NPC-L has taken off, at least in U.S. European Command, having a training mission on it, all the assets, and coordinating the integration from the ground piece to the in-flight piece,” said Capt. JD Pilger, 86th AES training flight commander. “Previously, everything was done on the ground, so this is a big deal. The capstone for the week was getting this thing airborne and proving this concept and capability for EUCOM.”

Operations such as these are historically placed within the Air Mobility Command, specifically at Joint Base Charleston, South Carolina. The initial force training was only conducted there for the entire Air Force, which would then piece together teams and send on deployments to provide this capability operationally.

In July, however, AMC started a flagship initiative to send certified trainers to Ramstein AB to certify 86th Medical Group and 86th AES personnel to be the initial cadre on the NPC-L. This established an organic capability located overseas, therefore widening the pool of certified personnel to the force, said Maj. Josh Williams, 86th AES operations flight commander.

From the 721st Aerial Port Squadron, loading the NPC-L onto the aircraft to the 86th MDG and 86th AES infectious disease team ensuring proper personal protective equipment was worn during each scenario, multiple units were called upon to contribute to the training.

“The training was for developing another force package for the 86th AW, to enable us to move COVID-positive patients utilizing the NPC-L,” Pilger said. “The force package entails members from the 86th MDG, the 86th AES and additional folks over at Landstuhl Regional Medical Center, such as our Critical Care Air Transport Team.”

The NPC-L is a smaller version of the Negatively Pressurized Conex, an isolated containment chamber intended to transport individuals with infectious diseases like COVID-19. While the NPC is used on C-17 Globemaster III, the NPC-L was developed for use on a C-130J.

“Pursuant to a U.S. Transportation Command joint urgent operational need request, (the NPC) was fielded, and the follow on to that was the NPC-L,” Williams said. “That is what we’ve now developed our teams and force packages within the 86th AW to support. (The NPC) is actually loadable on a C-130 and can transport patients in EUCOM, as well as U.S. Africa Command.”

Up to nine ambulatory patients, four litter patients, two CCATT critical care patients, or variations thereof, can be transported in the NPC-L.

During the training, Airmen were presented with various patient-transfer scenarios and worked together to execute the mission both on the ground and in the air.

“It was a true team sport throughout the whole thing,” said Capt. Zachary Gooch, 86th AES operations support flight commander. “We could not have done it without the support from Air Terminal Operations Center, maintenance or the medical group.”

Having this organic capability enables Ramstein to provide COVID-19 patient movement overseas without the need for assets deployed from AMC.

“I think we proved that this can be done without having a deployed asset that rolls in and sets up shop,” Gooch said. “We did it, basically, from grassroots.”

By SrA John R. Wright, 86th Airlift Wing Public Affairs

S.O.Tech Reaches a 300,000 Mask Milestone While Incurring a Sad Loss

Thursday, December 31st, 2020

It was with great pride that this week the S.O.Tech team delivered our 300,000th cloth facecover, but that news turned somber when we learned that a dear friend to the company, Deputy Tim Tellez, died battling COVID-19. So we dedicate our accomplishment to Tim’s memory, and we will continue the effort for Tim and other fallen first responders.

If you’ve seen a picture of police gear on SOTECH’s website, it was probably strapped onto Tim, we just cut his face out and blurred his name badge. He took gear design to heart and was always there to give thoughts and feedback on patrol officer gear because he cared about his fellow LEOs.  He was a 20 year veteran of LASD. We will be making a donation in his honor.

Not only was S.O.Tech able to deliver the 300,000 masks, but we have been able to fill major military, aerospace and law enforcement contracts in the face of a pandemic strained supply line.  We are proud of the teamwork exhibited by our staff.

The Army’s Official Face Mask to be Issued to New Soldiers in 2021

Thursday, December 17th, 2020

The official Army-designed, -tested, and -refined face mask – the Combat Cloth Face Covering (CCFC) – will be provided to new Soldiers during the second quarter of FY2021. This was one of the updates provided to the Army Uniform Board (AUB) during its 152nd meeting, which occurred on Nov. 18.

In response to the current pandemic, the Army has largely provided disposable or reusable, solid color masks to Soldiers who have also been permitted to use neck gaiters and other cloth items, such as bandanas and scarves, as face coverings. This past summer, the Army Uniform Board recommended and General James C. McConville, the U.S. Army Chief of Staff, approved issuing CCFCs to Soldiers at Initial Entry Training (IET) as part of their clothing bag. At the 152nd AUB, Army officials said that the Defense Logistics Agency (DLA) will begin issuing two CCFCs to each new Soldier during the second quarter of FY2021. The CCFCs will likely be available for purchase at the Army & Air Force Exchange Service (AAFES) uniform stores later in FY2021. (Note: Existing guidance on face coverings for current Soldiers remains unchanged and can be found at the end of this article.)

The CCFC was designed, developed, and produced along an expedited timeline. It normally takes 18–24 months for DLA to have the item available for order once the technical description, design, and components are approved and submitted. The CCFC, from inception to issuance, is slated to take less than one year.

The AUB also received updates on the implementation status of four other uniform changes from the 151st AUB, which took place in June 2020. A summary of these follow:

Improved Hot Weather Combat Uniform-Female (IHWCU-F): Expected to be added to the clothing bag in the fourth quarter of FY2021 and available for purchase in the second quarter of FY2022.

Hot Weather Army Combat Boot-Improved (HW ACB-I): Expected to transition to DLA Troop Support for new contracting action in the second quarter of FY2021 and be available for purchase by FY2024.

Black Athletic Socks: DLA estimates the sock will be available in the clothing bag in second quarter of FY2022.

Army Physical Fitness Uniform-Maternity (APFU-M): Prototypes are in development. The Army is working with the Air Force and Marines on their past maternity uniform efforts in order to expedite pattern development. Form, fit, and function evaluations are expected to occur in the third quarter of FY2021.

The AUB also discussed additional clothing articles, including items for new and expecting mothers. More information will be provided about these discussions in 2021 after Senior Leader decisions are made.





By Kinsey Kiriakos

Chargeurs Invests in Reshoring PPE Manufacturing to the US

Tuesday, October 13th, 2020

Company Creates More than 50 New Jobs in Ohio and Prioritizes the Hiring of Veterans

U.S. Representative Warren Davidson to Tour Facility as Congress Considers Bipartisan Legislation in Support of More Domestic Manufacturing

New York, NY – October 13, 2020 –The Chargeurs Group today announced a significant investment to expand the company’s U.S. manufacturing footprint to reshore personal protective equipment (PPE) production. The project will support Chargeurs’ newest division, U.S.-based Lainiere Health & Wellness, which will oversee the distribution, marketing and sales of all U.S.-manufactured PPE, including consumer-grade and medical-grade three-ply masks as well as 95-level respirator masks. The company will welcome U.S. Representative Warren Davidson at its Troy, Ohio, facility, Novacel Inc., which is creating more than 50 new jobs in the state and prioritizing the hiring of military veterans.

“Chargeurs is highly committed to developing new industrial capacity in the U.S. and to contributing to the country’s ability to manufacture PPE domestically,” said Michaël Fribourg, Chairman and CEO of Chargeurs Group. “We are grateful to all of our U.S. teams for their own longstanding commitment to success and we will continue to invest in our American manufacturing capability in the coming years.”

Chargeurs’ Ohio manufacturing facility is in a district represented by Representative Warren Davidson, a former Army Ranger who spent 15 years owning and operating manufacturing companies in Ohio. Congressman Warren continues to champion Ohio manufacturing and his tour of Chargeurs’ facility in Troy follows the introduction of bipartisan legislation by Ohio Senator Rob Portman and Michigan Senator Gary Peters that would incentivize more American companies to reshore production of PPE, reducing the U.S.’s reliance on foreign-made supplies. Should it be signed into law, the Make PPE in America Act would require the federal government to issue long-term contracts to companies to produce PPE in the U.S. The law would help provide manufacturers with the certainty they need to justify an investment in U.S. production.

“I love seeing this growth in manufacturing in southwest Ohio,” said Congressman Davidson, who represents Ohio’s 8th District. “As we’ve seen this year, keeping production inside the U.S. isn’t just important for the economy, it is critical to our national security. As a former manufacturer and Army Ranger, I’m also glad to see that hiring veterans is a priority for businesses. This is a win-win for all involved.”

When the COVID-19 pandemic revealed the risk of relying on foreign countries for PPE, Chargeurs began retrofitting part of its Troy, Ohio, manufacturing facility to help alleviate the domestic shortage of this critical equipment. The facility has begun with lines that can produce up to 2.5 million masks a month and will increase its production capacity in the coming months. Chargeurs also aims to produce Berry-compliant masks that meet the requirements of US military and government contracts by the end of the year.

“Chargeurs has invested significant capital in retooling our Ohio factory to reshore production of PPE to America,” said Angela Chan, CEO and President of Chargeurs*PCC Fashion Technologies. “We have been supplying raw materials to the PPE market for years, so it made perfect sense to pivot to manufacturing these products in the USA, especially given the severe shortages of this equipment our country has seen since the start of the pandemic.”

“We could not be prouder to leverage our technical expertise in materials and textiles to help fill the urgent need for these supplies and to bring jobs—including jobs for veterans—back to Ohio,” added Laurent Derolez, CEO of Chargeurs Protective Films and President of Novacel Inc.

“Reshoring production of PPE items like masks is critical to prevent a repeat of the supply chain breakdown that caused major shortages earlier this year,” said Mark McCormick, Manufacturing Growth Specialist at FASTLANE, West Central Ohio’s Manufacturing Extension Partnership, which is located within the University of Dayton Research Institute. “The investment that Chargeurs is making in Troy will help to ensure that Americans have the PPE they need while also creating additional jobs for our region.”

The Troy Facility Is Just One Example of Chargeurs’ Commitment to Made in the USA Manufacturing

Chargeurs is a France-based, family-owned diversified group operating as a worldwide leader in various businesses, including technical and performance textiles for the apparel and fashion industry, surface protection solutions, and business services and fabrication for the museum, cultural and entertainment sectors. Under Michaël Fribourg’s leadership, Chargeurs has been investing in the U.S. since 2015 to support a strong Made in the USA strategy.

In addition to its investment in the Novacel Inc. facility in Ohio (formerly known as Troy Laminating & Coating), Chargeurs has invested in manufacturing technologies in a number of its other U.S. facilities, including Main Tape Company Inc. in New Jersey, Walco Inc. in California, Lainiere de Picardie Inc. in Pennsylvania, Design & Production Incorporated in Virginia, and Chargeurs Wool USA Inc. in South Carolina.

Outdoor Research Earns FDA EUA Authorization for its US-Made Surgical Mask

Thursday, August 27th, 2020

Seattle-based company one of only four companies to achieve FDA authorization for U.S.-made surgical masks since pandemic began

SEATTLE, Wash. – Outdoor Research, LLC. (OR), a leading brand in the tactical and outdoor apparel industries, has earned U.S. Food and Drug Administration Emergency Use Authorization (EUA) for its U.S.-made surgical mask. This authorization is designed to help strengthen the availability of key products needed during public-health emergencies. 

FDA EUA authorization follows quickly on the heels of National Institute for Occupational Health and Safety (NIOSH) approval in late July of OR’s Flat Fold Respirator Mask. NIOSH is a division of the U.S. Center for Disease Control and Prevention (CDC). 

Federal authorization of OR’s personal protective equipment (PPE) is the culmination of a months-long effort and represents two significant accomplishments. OR is one of only four organizations to achieve FDA authorization for U.S.-made surgical masks since the COVID-19 pandemic began. OR is also one of only six organizations to achieve expedited NIOSH certification to make healthcare respirators since the beginning of the pandemic. It is the only manufacturer within the outdoor and tactical spaces to do either. 

While many companies have entered the mask market temporarily by creating “face coverings” for general public use, OR has made a strategic commitment to expanding the company’s manufacturing capabilities to build advanced medical-devices, providing PPE to frontline healthcare workers during and after this current crisis. 

“With the onset of COVID-19, it quickly became clear that securing more reliable sources of medical PPE within the U.S. was critical to our country’s response to this pandemic,” said Jason Duncan, Head of Tactical, Innovation and CSR at Outdoor Research. “Because Outdoor Research already had long-established U.S. manufacturing capabilities and the know-how to quickly pivot to building new kinds of technical products, we are able to be part of the solution. These FDA and NIOSH authorizations speak to the success of that effort and to the vast amount of team work that has gone into this here at Outdoor Research.” 

In the past five months, OR invested in equipment and training to convert two floors of its Seattle manufacturing facility to produce two different types of N95 masks as well as medical-grade surgical masks. The company also produces the Berry Amendment-compliant Resolute Face Mask in Seattle. Along with investing in equipment, OR has hired more than 130 people to support mask production. These investments have resulted in the capability to produce up to 200,000 U.S.-made masks per day. To date, it has produced more than 3 million U.S.-made masks. 

OR is also producing reusable, technical and functional face masks for the general public. Like the Resolute Face mask, the Essential Face Mask Kit features an integrated and replaceable filter. 

Highly respected in the outdoor industry for developing functional solutions for extreme environments, OR has a history of successfully leveraging the best commercial market technologies to serve the needs of the armed services and first responders. Over the past two years the company has conducted a comprehensive review of the U.S. supply chain and is in active development with textile mills and materials providers to expand and elevate the capabilities of products that are 100% American-made.

OR has made significant capital investments designed to improve and modernize its Seattle factory. These investments have taken advantage of the company’s global knowledge of design, materials, and innovative manufacturing techniques while producing the next generation of outdoor and tactical products at its facilities. OR has continued to accelerate its product-development cycle, allowing the latest innovations to be rapidly fielded to the end user, helping increase the mobility and protection of soldiers, sailors, airmen, marines, first responders, outdoor enthusiasts, and now the medical community.  

For more about Outdoor Research, visit

ADS Federal Range Day 20 – CBR Multi-Purpose Wipe from M2DCON

Tuesday, August 25th, 2020

Pouches of the CBR Multi-Purpose Wipe from M2DCON were everywhere during Federal Range Day. These is a commercial equivalents to the US DoD Joint Service Equipment Wipe (JSEW/M334) were used to decon a wide variety of equipment between users. Even though the wipe is safe for personal hygiene, it has also been certified to neutralize against chemical (nerve, blister and other agents of concern) and biological (bacteria, viruses and spores) contamination.

Units and agencies can procure all products shown during ADS Federal Range Day by contacting ADS Inc.